

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the error caused by improper filing of Security Agreement previously recorded on Reel 027464 Frame 0745. Assignor(s) hereby confirms the Assignee: Talon Therapeutics, Inc. as per Affidavit under MPEP 323 AND 323.01(C).
CONVEYING PARTY DATA	
Name	Execution Date
Talon Therapeutics, Inc.	03/20/2012
RECEIVING PARTY DATA	
Name:	Talon Therapeutics, Inc.
Street Address:	2207 Bridgepointe Parkway, Suite 250
City:	San Mateo
State/Country:	CALIFORNIA
Postal Code:	94404
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7452550
CORRESPONDENCE DATA	
Fax Number:	(617)742-4214
Email:	lindsay.millette@nelsonmullins.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Nelson Mullins Riley & Scarborough LLP
Address Line 1:	One Post Office Square, 30th Floor
Address Line 4:	Boston, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	HBJ-020BDV2
NAME OF SUBMITTER:	Jane E. Remillard, Esq.
Total Attachments: 11 source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page1.tif source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page2.tif	

CH \$40.00 7452550

source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page3.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page4.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page5.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page6.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page7.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page8.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page9.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page10.tif
source=HBJ-020BDV2 Corrected Assignment Package 3-23-12#page11.tif

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: March 23, 2012
Electronic Signature for Jane E. Remillard, Esq.: /Jane E. Remillard, Esq./

Docket No.: HBJ-020BDV2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Thomas D. Madden *et al.*

Patent No.: 7,452,550

Confirmation No.: 3882

Issue Date: November 18, 2008

Art Unit: 1612

For: LIPOSOMAL ANTINEOPLASTIC DRUGS
AND USES THEREOF

Examiner: G. S. KISHORE

MS: Assignment Services Branch
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

AFFIDAVIT UNDER MPEP § 323 AND § 323.01(C)

I do hereby swear that the following:

1. I am a partner at the law firm of NELSON MULLINS RILEY & SCARBOROUGH LLP. My firm serves as patent counsel to Talon Therapeutics, Inc.
2. I hereby submit this affidavit in accordance with MPEP § 323 and § 323.01(c) for the above-identified U.S. Patent. The Security Agreement between Terkmira Pharmaceuticals Corporation and Silicon Valley Bank recorded under Reel/Frame 027464/0745 was improperly filed. Specifically, attached is a copy of an executed Assignment which establishes that Tekmira Pharmaceuticals Corporation assigned their ownership rights to Talon Therapeutics, Inc. prior to the execution of the above-identified Security Agreement.
3. I further submit herewith a Release of Security Interest executed by Silicon Valley Bank on March 20, 2012, which further acknowledges that Talon Therapeutics, Inc. is the sole assignee of the above-identified Patent.

4. I declare that the true chain of title should be as follows:

Assignment: 1	Reel/Frame: 027610/0271
Assignors:	Madden, Thomas D. Semple, Sean C. Ahkong, Quet F.
Assignee:	Inex Pharmaceuticals Corporation
Assignment: 2	Reel/Frame: 019287/0612
Assignor:	Inex Pharmaceuticals Corporation
Assignee:	Tekmira Pharmaceuticals Corporation
Assignment: 3	Reel/Frame: 027593/0712
Assignor:	Tekmira Pharmaceuticals Corporation
Assignee:	Talon Therapeutics, Inc.

5. I further declare that Talon Therapeutics, Inc. has been and continues to be, the sole assignee of the above-identified U.S. Patent pursuant to the aforementioned assignment document. Accordingly, correction of the record is respectfully requested.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of this Patent.

Dated: March 23, 2012

Respectfully submitted,

Electronic signature: /Jane E. Remillard, Esq./
Jane E. Remillard, Esq.
Registration No.: 38,872
NELSON MULLINS RILEY &
SCARBOROUGH LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(800) 237-2000
(617) 742-4214 (Fax)
Attorney/Agent For Applicant

ASSIGNMENT

WHEREAS, **Tekmira Pharmaceuticals Corporation**, a Corporation organized under the laws of Canada, located at 8900 Glenlyon Parkway, Burnaby, British Columbia V5J 5J8, Canada (hereinafter "ASSIGNOR"), for valuable consideration provided by

Talon Therapeutics, Inc.

a Corporation of Delaware, having its principal place of business at 2207 Bridgepointe Parkway, Suite 250, San Mateo, California 94404 (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Talon Therapeutics, Inc.


its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention(s) or improvement(s) described in the patents and applications listed in attached Schedule A, and in all Letters Patent(s) of the United States and all foreign countries which may or shall be granted on said invention(s), or any parts thereof, or on said application(s), or any divisional, continuing, reissue or other applications based in whole or in part thereon.

And ASSIGNOR agrees, with Talon Therapeutics, Inc. and its successors and assigns, to hereafter assist to the best of ASSIGNOR's ability with the execution of all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to Talon Therapeutics, Inc., with specifications and claims in such form as shall be approved by the counsel of Talon Therapeutics, Inc. and to vest and confirm in Talon Therapeutics, Inc., its successors and assigns, the legal title to all such patents.

And ASSIGNOR and ASSIGNEE agree that Talon Therapeutics, Inc. and its successors and assigns, will hereafter assume all expense and charges associated with prosecution of the patent(s) and application(s) described in Schedule A.


And ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to Talon Therapeutics, Inc., its successors and assigns.




Mark J. Murray, Ph.D.
President and Chief Executive Officer
Tekmira Pharmaceuticals Corp.


OCTOBER 24 2011
(date)


On this 24 day of OCTOBER, 2011 before me,
the undersigned notary public, personally appeared Mark J. Murray, Ph.D.
proved to me through satisfactory evidence of identification, which was
USA PASSPORT No. 077691889, to be the person whose name
is signed on the preceding or attached document in my presence.

 (official signature and seal of notary)

My commission expires PERMANENT

ELISABETH RECHSTEINER
Notary Public
100 - 5050 Kingsway
Burnaby BC V5H 4C2 Canada
(604) 433-1911
(Permanent Commission)





Name: STEVEN R DEITCHER
Title: PRESIDENT + CEO
Talon Therapeutics, Inc.

3 November 2011
(date)

On this 3 day of November, 2011 before me,
the undersigned notary public, personally appeared Steven Deitcher
proved to me through satisfactory evidence of identification, which was
CA driver license, to be the person whose name
is signed on the preceding or attached document in my presence.

Irina Eilen (official signature and seal of notary)

My commission expires June 25, 2012






Schedule A

Attorney Docket No.	Title	Country	Patent No./Serial No.	Inventors	Status
HBJ-020A	LIPOSOMAL CAMPTOTHECINS AND USED THEREOF	United States	09/896,811 7,060,828	Thomas D. Madden, Sean C. Semple	Issued
HBJ-020APC	IMPROVED LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	Patent Cooperation Treaty	PCT/ CA2001/00981	Thomas D. Madden, Sean C. Semple	Expired
HBJ-020ACA	IMPROVED LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	Canada	2412795	Thomas D. Madden, Sean C. Semple	Pending
HBJ-020ADE	IMPROVED LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	Germany	01949169.5 1299085	Thomas D. Madden, Sean C. Semple	Granted
HBJ-020AEP	IMPROVED LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	European Patent Convention	01949169.5 1299085	Thomas D. Madden, Sean C. Semple	Granted
HBJ-020AES	IMPROVED LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	Spain	01949169.5 1299085	Thomas D. Madden, Sean C. Semple	Granted
HBJ-020AFR	IMPROVED LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	France	01949169.5 1299085	Thomas D. Madden, Sean C. Semple	Granted

Attorney/Docket No.	Title	Country	Patent No./Serial No.	Inventors	Status
HBJ-020AGB	IMPROVED LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	Great Britain	01949169.5 1299085	Thomas D. Madden, Sean C. Semple	Granted
HBJ-020ACN	LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	United States	11/294826	Thomas D. Madden, Sean C. Semple	Abandoned
HBJ-020ACN2	LIPOSOMAL CAMPTOTHECINS AND USES THEREOF	United States	12/963888	Thomas D. Madden, Sean C. Semple	Pending
HBJ-020B	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	United States	09/896,812 7,244,448	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Issued
HBJ-020BPC	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Patent Cooperation Treaty	PCT/CA2001/00925	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Expired
HBJ-020BAU	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Australia	2001270385	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted
HBJ-020BCA	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Canada	2412790	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Pending
HBJ-020BCI	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	China	01813818.7 ZL 01813818.7	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted

Attorney Docket No.	Title	Country	Patent No./Serial No.	Inventors	Status
HBJ-020BDE	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Germany	01949141.4 1299084	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted
HBJ-020BEP	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	European Patent Convention	01949141.4 1299084	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted
HBJ-020BFR	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	France	01949141.4 1299084	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted
HBJ-020BGB	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Great Britain	01949141.4 1299084	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted
HBJ-020BIL	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Israel	153676	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted
HBJ-020BJP	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Japan	2002-506699	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Pending
HBJ-020BMX	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Mexico	PA/a/2002/012817 279046	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted
HBJ-020BSG	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	Singapore	200207882-2 94091	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Granted

Attorney Docket No.	Title	Country	Patent No./Serial No.	Inventors	Status
HBJ-020BDV	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	United States	10/788649	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Abandoned
HBJ-020BCNRCE	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	United States	11/429911	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Pending
HBJ-020BDV2	LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF	United States	11/430,522 7,452,550	Thomas D. Madden, Sean C. Semple, Quet F. Ahkong	Issued

RELEASE OF SECURITY INTEREST

This Release of Security Interest is executed as of March 20, 2012 by Silicon Valley Bank ("Bank") for the benefit of Talon Therapeutics, Inc., a Delaware corporation ("Assignee").

RECITALS

A. WHEREAS, Assignee was assigned the entire interest in the United States and all foreign countries in the intellectual property described on Exhibit A (the "Tekmira IP"), including any divisional, continuing, reissue or other application based in whole or in part thereon, pursuant to a certain Assignments dated November 3, 2011 and April 30, 2007, by and between the Assignee and Tekmira Pharmaceuticals Corporation, a corporation organized under the laws of Canada ("Tekmira"), as recorded with the U.S. Patent and Trademark Office on January 25, 2012;

B. WHEREAS, Bank was granted, among other things, a security interest in all of Tekmira's right, title and interest in the Tekmira IP, pursuant to a certain intellectual property security agreement, dated as of December 21, 2011, by and between Bank and Tekmira, and recorded with the U.S. Patent and Trademark Office on December 29, 2011; and

C. WHEREAS, Bank wishes to release all interest that Bank may have in the Tekmira IP throughout the world including all re-issues, divisionals, continuations, renewals, extensions and continuations-in-part thereof.

AGREEMENT

Now, therefore, Bank agrees that it releases all security interest in the Tekmira IP to Assignee, without warranty or recourse,

ASSIGNOR:

Address:

3003 Tasman Drive
Santa Clara, CA 95054

SILICON VALLEY BANK

By: 

Title:

Relationship Manager

EXHIBIT A

Patents

<u>Description</u>	<u>Patent/App. No.</u>	<u>File Date</u>
Liposomal antineoplastic drugs and uses thereof	10788649	02/27/04
Liposomal camptothecins and uses thereof	11294826	12/06/05
Liposomal antineoplastic drugs and uses thereof	11429911	05/08/06
Compositions and methods for treating lymphoma	12069488	02/11/08
Liposomal camptothecins and uses thereof	7060828	06/13/06
Liposomal antineoplastic drugs and uses thereof	7244448	07/17/07
Liposomal antineoplastic drugs and uses thereof	7452550	11/18/08
Liposomal camptothecins and uses thereof	12963888	12/09/10